معرفی
John Löfblom is a Professor at KTH Royal Institute of Technology specializing in Combinatorial Protein Technology. His research focuses on engineering proteins for medical applications, particularly in diagnostics and therapies for cancer and neurodegenerative diseases. He employs advanced techniques like directed evolution and combinatorial libraries to develop affinity proteins such as affibodies.
His work includes creating protein-based drugs, prodrugs activated by cancer-associated proteases, and diagnostic tools like PET imaging agents targeting HER3, PDGFRβ, and CD69. Löfblom’s methods involve bacterial display systems (E. coli, staphylococci) for protein selection and optimization of radiolabeled affibody molecules for in vivo imaging.
Key projects include:
- Development of HER3-targeted therapeutics and imaging probes
- Design of sequestrins to inhibit amyloid aggregation in Alzheimer’s
- Pioneering PET imaging solutions for early disease detection (e.g., fibrogenesis, inflammatory arthritis)
- Engineered proteins for BBB-crossing drug delivery systems
His research bridges biotechnology and clinical translation, emphasizing preclinical efficacy and molecular imaging contrast optimization.
